100 Albert Road
Level 4
Melbourne, VIC 3205
Australia
61 3 9692 7222
https://www.inviongroup.com
Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees:
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Thian Chew | Executive Chairman & CEO | 365.67k | N/A | N/A |
Ms. Melanie Jaye Leydin B.Bus, C.A. | Chief Financial Officer | N/A | N/A | 1973 |
Dr. Dean Naylor | Head of Intellectual Property Development | N/A | N/A | N/A |
Ms. Claire Newstead-Sinclair C.A. | Company Secretary | N/A | N/A | N/A |
Invion Limited, a clinical-stage life-sciences company, researches and develops Photosoft technology for the treatment of various cancers, atherosclerosis, and infectious diseases in Australia. The company is developing IVX-PDT, a photosensitizer agent to treat skin cancers, as well as solid cancers, including lung, prostrate, ovarian, anogenital, and mesothelioma cancers. It has a research and development agreement with Hudson Institute of Medical Research to develop a novel photosensitiser for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion's IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer. Invion Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
Invion Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.